Verified by HPLC, compliant with global pharmacopoeial monographs, and manufactured in cGMP-audited lines.
Combining modern industrial hydro-ethanolic counter-current extraction with multi-stage membrane purification to isolate targeted bioactive metabolites.
We provide exact biomarker ratio balancing: from Total Triterpenic Fraction of Centella Asiatica (TTFCA 70%–95%) to pure isolated Asiaticoside (up to 98%) and Madecassoside (95%+), engineered without toxic solvent traces.
Full conformance with EP (European Pharmacopoeia), USP, and CP quality monographs. Heavy metals (< 10 ppm), ethylene oxide-free sterilization, and stringent polycyclic aromatic hydrocarbon (PAH4) limits ensure seamless regulatory clearance.
Micronized (up to 200 mesh) and cold-water-soluble Centella root powder options tailored for zero-sediment clear serums, beverage premixes, softgels, and topical lipid nano-carriers.
Centella Asiatica has shifted from an empirical folk herb to a clinically defined, multi-billion-dollar driver across dermocosmetic, dermatological, and nutraceutical pipelines.
Consumer demand has evolved beyond basic "soothing" claims. Modern clinical formulations target deep skin-barrier architecture, TGF-beta pathway stimulation for Type I & III collagen synthesis, and scar mitigation. Procurement teams now specify precise pentacyclic triterpene ratios rather than unstandardized 10:1 ratio powders to justify active efficacy claims on packaging.
Procurement teams regularly confront unvetted supply chains plagued by pesticide residue (chlorpyrifos, DDT), unauthorized wild harvesting, and heavy variability in glycoside versus aglycone content. Xi'an Le-Nutra mitigates this with contracted cultivation bases, batch-to-batch DNA fingerprinting, and full solvent residue verification (conforming with USP <467> Class 1, 2, and 3 guidelines).
Beyond topical serums, oral nutraceuticals targeting venous insufficiency, microvascular repair, and cognitive neuroprotection (via BDNF modulation) represent hyper-growth segments. Our food-grade and nutraceutical-grade Centella Asiatica Root Extracts offer granular organoleptic stability, low hygroscopicity, and superior shelf-life retention under accelerated stability testing.
Ensuring compliance across EMEA, FDA, NMPA, and APAC frameworks with verifiable technical transparency.
Every shipment is accompanied by bilingual technical dossiers: Batch COA, GC-MS & HPLC chromatograms, Allergen Statements, Non-GMO declarations, TSE/BSE certifications, and full CPNP / INCI registration dossiers for frictionless customs import clearance in North America, EU, Japan, and Southeast Asia.
Our ongoing technical roadmap incorporates cyclodextrin inclusion, liposomal encapsulation, and phospholipid complexation (Phytosome technology) of Asiaticoside and Madecassoside. This bypasses the typical barrier permeability challenges of polar triterpene glycosides, amplifying dermal bioavailability by up to 300%.
In accordance with ESG standards, our extraction process adopts closed-loop ethanol recovery systems exceeding 95% thermal recapture efficiency. Botanical biomass residue is fully neutralised for agricultural fertilization, ensuring your brand inherits an audited, low-carbon raw material footprint.
Technical resolutions for common QA questions, formulation compatibility queries, and commercial terms.
Combine high-potency Centella Asiatica with our validated active peptides, botanical fractions, and health concentrates.
Typical reply within one business day (UTC+8).
[email protected] +86-29-86518603 Request a Catalog Contact us